Lori West, MD, PhD (Chair)
Professor of Pediatrics and Surgery
Director of Heart Transplantation Research
Department of Pediatrics
University of Alberta
Dr. Lori West is the Director of Heart Transplantation Research and a Professor of Pediatrics and Surgery at the University of Alberta Stollery Children's Hospital - one of the largest heart transplant programs in the world.

Dr. West completed her paediatric residency at Harbor-UCLA Medical Center and came to the Hospital for Sick Children, Toronto in 1987 to complete a two-year clinical fellowship in paediatric cardiology. She obtained her PhD for specialized training in transplant immunology research at Oxford University.

Dr. West's research focuses on overcoming the body's immune system response to foreign tissue. She discovered that infant heart transplants can be performed safely and successfully despite major blood type incompatibility between the donor and recipient.

Dr. West has over 58 peer-reviewed publications, has contributed to policy and has been invited to make over 95 presentations at conferences around the world. She has been interviewed on national TV, radio and featured in newspapers across North America.

---

Paul W. Armstrong, MD
Professor of Medicine
University of Alberta
Dr. Paul Armstrong is Professor of Medicine in the Division of Cardiology at the University of Alberta, Edmonton, Alberta, Canada and Director of the Canadian VIGOUR Centre. He is Director of the CIHR program training grant TORCH (Tomorrow's Research Cardiovascular Health Professionals) that represents a synergistic partnership between the universities of Alberta and Calgary. He is a Senior Attending Cardiologist at the University of Alberta Hospital with particular interest and expertise in acute coronary care and heart failure. In the latter capacity he serves as Director of the University of Alberta Hospital Heart Function Clinic. Dr. Armstrong received his medical degree at Queen's University, Kingston, Ontario, Canada and after post-graduate training both there and at the University of Toronto, Ontario, Canada he undertook clinical and research training in cardiology at the Massachusetts General Hospital, Harvard Medical School, MA,USA and St. George's Hospital, London, UK.

Dr. Armstrong's investigative career has developed along two major lines of inquiry. The first involved the study of the pathophysiology and novel therapeutic approaches of congestive heart failure using an experimental model as well as undertaking clinical investigative studies. The second, which is now his principal focus, involves the pathophysiology, diagnosis and management of acute coronary syndromes. He has a particular interest in the analysis of international differences in the process of cardiovascular care and their implications for the Canadian health care system.

Dr. Armstrong is the author, or co-author of over 300 peer reviewed publications and a member of the editorial board of a number of publications, including the Canadian Medical Association Journal, Canadian Journal of Cardiology, the American Heart Journal and Circulation Section Editor of New Frontiers. He also serves as a member on the FDA Cardiovascular and Renal Drugs Advisory Committee. In 1993, Dr. Armstrong received the Research Achievement Award from the Canadian Cardiovascular Society, and in 1998, the Award of Merit from the Heart and Stroke Foundation of Canada for contributions to medical research.

---

Yves Berthiaume, MD, MSc.
Professor
Department of Medicine
Respiratory Division
Université de Montréal
Dr. Yves Berthiaume is currently a professor in the respiratory division of the department of medicine at Université de Montréal.

Dr. Berthiaume received his obtained his medical degree at the University of Sherbrooke in 1980, and subsequently trained there in internal medicine and respiratory medicine (1980-1983). He also received a Master of Science degree in physiology from the University of Sherbrooke (1983), and became a fellow of the Royal College of Physicians of Canada with certification in pulmonary medicine (1984). Dr. Berthiaume completed a fellowship at the Cardiovascular Research Institute at the University of California, San Francisco (1983-1986). From 1986 to 1992, he was an assistant professor and associate professor of medicine at the University of Calgary. He became a member of the pulmonary division and a member of research center at The Centre Hospitalier de l'Université de Montréal in 1992.

Dr. Berthiaume's research interests are focused on the role of sodium transport in the pathophysiology of cystic fibrosis and ARDS. Specifically, he focuses on the modulation of expression and activity of the sodium channel ENaC in lung epithelial cells, and its relevance to epithelial dysfunction in these pathologies.

Dr. Berthiaume has participated on numerous peer reviews committees at the national and provincial level, including CIHR and Fonds de recherche en santé de Québec (FRSQ). He's currently the chair of the Medical and Scientific Advisory Committee of the Canadian Cystic Fibrosis Foundation.

---

Dr. James A. Dosman
Dr. James A. Dosman was appointed a member of the Canadian Nuclear Safety Commission in June, 2002.

A native of Humboldt, Saskatchewan, Dr. Dosman received a Master of Arts in 1969, a Doctor of Medicine in 1963, and a Bachelor of Arts in 1959, all from the University of Saskatchewan. He is currently Director of the Centre for Agricultural Medicine, and Head of the Division of Agricultural and Occupational Medicine at the University of Saskatchewan. Dr. Dosman is also a Fellow of the Royal College of Physicians and Surgeons of Canada and a professor in the Department of Medicine at the University of Saskatchewan. He has also served as the Medical Director of the Pulmonary Function Laboratory (1976-1984) and Medical Director of Respiratory Therapy Services (1978-1983, 1985-86), both at the University Hospital. In 1983-84, Dr. Dosman was visiting professor at the University of Toronto in the Department of Epidemiology and Biostatistics. He is an Associate Member of the Western College of Veterinary Medicine and the Department of Community Health and Epidemiology. Dr. Dosman's fields of expertise include respiratory diseases and agricultural medicine.

Dr. Dosman's honours include receipt of a Distinguished Scientist Award from the Medical Research Council of Canada (1998) and numerous fellowships and scholarships in medical research including Research Scholar, Health Canada (1988-1989, 1990-1994), Ferguson Professor of Respiratory Diseases, University of Saskatchewan (1975-1984), Fellow, American College of Chest Physicians (1980) and Lifetime Membership, Saskatchewan Lung Association (1979).

---

Dr. Marshall Godwin
MD (Mem,1977), MSc Epidem. Queen's, 1998), CCFP (1979)
Professor of Family Medicine, Memorial University
Director, Primary Healthcare Research Unit
Research Interests: Hypertension, Care of the Elderly, Chronic Disease, Lifestyle and CVS Disease
Publications: 69 journal article, 2 books, 3 book chapters
Currently holds research grants from CIHR and the Heart and Stroke Foundation

Dr. Godwin worked in rural practice for 8 years prior to moving St. John's, NL with the Discipline of Family Medicine at Memorial University 1987. In 1993 he moved to Queen's University in Kingston, Ontario as Director of the Centre for Studies in Primary Care. In 2000/2001 Dr. Godwin spent a year at the Centre for Evidence Based Medicine in Oxford, England. In 2005, he moved back to Memorial University to take up his current position. Currently Dr. Godwin's work is divided between clinical practice (30%) and research (70%).

---

Tara Haas, PhD
Associate Professor
School of Kinesiology and Health Sciences
York University
Dr. Tara Haas is currently an associate professor in the School of Kinesiology and Health Sciences at York University.
She completed her bachelor's degree in human kinetics at the University of Guelph (1990), her PhD in physiology at the University of Virginia (1995) and received postdoctoral training at Yale University (1999) prior to taking a faculty position at York. Dr. Haas's research program focuses on the process of angiogenesis, new capillary growth within skeletal and cardiac muscle, and understanding how this process may be stimulated by exercise. A major component of this research involves mapping the intracellular signaling and transcriptional regulation of matrix metalloproteinases within endothelial cells, as these enzymes play a critical role in early phases of angiogenesis.

Dr. Haas currently holds a CIHR New Investigator Award, Premiers Research Excellence Award, and funding from the Natural Sciences and Engineering Research Council (NSERC) and the National Institutes of Health (NIH). She is a council member for the Microcirculatory Society.

---

Pavel Hamet, MD, PhD, CSPQ, FRCP
Directeur de la recherche
Centre Hospitalier
Université de Montréal (CHUM)
A Canadian citizen, born in the Czech Republic, Dr. Pavel Hamet completed his medical studies at Charles University, Prague. After being awarded a Centennial Fellow from the Medical Research Council in 1973, he studied endocrinology and physiology at Vanderbilt University, Nashville, Tennessee, from July 1973 to June 1975. He is Director of Research, Research Centre of the Centre hospitalier de l'Université de Montréal, and Professor at the Departments of Medicine, Physiology and Nutrition at the University of Montreal and Adjunct Professor at the Department of Medicine at McGill University. Dr. Hamet is the author and co-author of over 350 manuscripts, published in well-recognized peer-reviewed journals and books of scientific interest.

Dr. Hamet receives financial support from major funding institutions, such the Medical Research Council of Canada and the National Institutes of Health (USA) as well as from the pharmaceutical industry. He was President of the Canadian Hypertension Society and Secretary of the International Society of Hypertension. He received many prizes, including the "Harry Goldblatt Award" from the American Heart Association in 1990 for his achievements in the field of hypertension. In 1994, he was appointed Honorary Professor of the Shanghai II Medical University, Shanghai, China and he received the Golden Medal of J.E. Purkyne of the Czech Academy of Sciences, Prague, Czech Republic the same year. In 1996, Dr. Hamet received the Distinguished Scientist Award of The Canadian Society for Clinical and the Achievement Award of the Canadian Cardiovascular Society in 1998.

Dr. Hamet serves on many national and international boards including Medical Research Council of Canada/Rx&D, Institut national de la recherche scientifique (INRS), Centre d'entreprises et d'innovation de Montréal, BioCapital Inc., PharmaVision Inc., Montreal TechnoVision Inc., Vasogen Inc., ConjuChem Inc., Angiogene Inc.

---

Qutayba Hamid, MD, PhD
Professor
Faculty of Medicine
McGill University
Dr. Qutayba Hamid is a professor of medicine at McGill University. He is the Director of the Respiratory Axis at the University Health Centre Research Institute and the Associate Director of the Meakins-Christie Laboratories. He has been awarded the prestigious James McGill Chair and more recently the MUHC Strauss Chair in Respiratory Medicine at McGill.

Dr. Hamid received his medical degree from Mosul University in Iraq in 1977 and his PhD from the University of London in the United Kingdom in 1988. In 1993, he was appointed professor at McGill University and the Meakins-Christie Laboratories. Dr. Hamid's primary areas of research interest include pathogenesis of asthma, allergic rhinitis, the role of cytokines and chemokines in allergic diseases, new therapies for asthma treatment and allergic rhinitis, and pathogenesis of chronic obstructive pulmonary disease (COPD).

Dr. Hamid has published over 300 scientific articles in prestigious international journals and has contributed more than 90 chapters and review articles. He has been a visiting professor worldwide at universities in Japan, USA and Europe. He is currently the associate editor of the Journal of Allergy and Clinical Immunology, and Journal of Clinical and Experimental Allergy, as well as Section Editor for Journal of Allergy, Asthma, and Clinical Immunology.

He is also a member of many scientific and professional organizations, including the Royal College of Physicians in both the United Kingdom and in Canada, the American Thoracic Society, the Canadian Society of Allergy and Clinical Immunology, the American Academy of Allergy, and the Royal College of Pathologists.

---

Dr. Michael Hill
Dr. Hill's research interests include clinical trials in stroke and the use of administrative data for stroke research and surveillance. He has participated in multiple clinical trials, leads the Calgary Stroke Program Clinical Trials Group and is leading four large clinical trials as the PI, co-PI or Steering Committee member. He has made contributions to the understanding of acute stroke thrombolytic treatment that has helped patients worldwide heal from the devastation of stroke-related brain injury.

He has begun fundamental work on stroke surveillance using administrative data to monitor stroke rates and stroke outcomes.

Michael Hill was born in Toronto, ON and received undergraduate training in Biochemistry at McGill University (BSc 1989). He completed medical school and an internal medicine residency at the University of Ottawa (MD 1993 and FRCPC 1997). He undertook further residency training in neurology at the University of Toronto (FRCPC 1999) and moved to Calgary in July 1999. There he completed fellowship training in Stroke Neurology and received a Master's degree in Clinical Epidemiology (MSc 2003). He joined the faculty of medicine in 2001. He is currently primarily appointed as Associate Professor in the Department of Clinical Neurosciences with cross-appointments to Medicine and Community Health Sciences.

He is currently holds the Heart & Stroke Foundation of Alberta/NWT/NU Professorship in Stroke Research and is the Director of the Stroke Unit.

In recognition of his research contributions Dr. Hill has received:

• Henry J.M. Barnett Scholarship for Stroke Research (2001)
• Francis McNaughton Award from the Canadian Neurological Society (2002)
• Michael S. Pessin Stroke Leadership Prize from the American Academy of Neurology (2004)

Dr. Hill has been funded by the Canadian Institutes of Health Research (CIHR), Heart & Stroke Foundation of Alberta/NWT/NU and the NINDS (NIH) since 2001. He was awarded an AHFMR Health Scholarship in 2007. He has published 107 peer-reviewed original articles and 25 review articles and editorials.

---

Kathryn King, PhD
Associate Professor and Heritage Population Health Investigator
Faculty of Nursing
University of Calgary
Dr. Kathryn King is an Associate Professor and Heritage Population Health Investigator in the Faculty of Nursing and Department of Community Health Sciences at the University of Calgary. She earned a BSc in Nursing from McMaster University in 1980 and a Masters and PhD in Nursing from the University of Alberta in 1993 and 1997 respectively. She undertook post-doctoral training in the Faculty of Medicine, Division of Cardiology (EPICORE Centre) between 1997 and 1999 and was appointed to the University of Calgary in 1999. Her multi-methods program of research, funded by AHFMR, SSHRC and CIHR, focuses on recovery from cardiac events. In particular she has examined the influences of gender/sex and ethnocultural affiliation on various components of cardiac recovery. Dr. King served as the national research chairperson for the Canadian Council of Cardiovascular nurses between 1998 and 2003.

---

Marlys L. Koschinsky, PhD
Dr. Koschinsky was born in Winnipeg and obtained her undergraduate degree in Biology from the University of Winnipeg in 1982. She subsequently completed her PhD in Biochemistry at the University of British Columbia in 1988 and joined the Cardiovascular Research Group at Genentech, Inc. (San Francisco, California) as a Medical Research Council (MRC)-funded post-doctoral fellow.

It was during her post-doctoral studies that she developed a research interest in structure/function analyses of lipoprotein(a), which had been characterized at Genentech, and had been identified in population studies as a risk factor for coronary heart disease. Funded by a salary award from the Natural Sciences and Engineering Research Council of Canada, Dr. Koschinsky accepted a position at Queen's University as an Assistant Professor in 1991, and initiated a research program focused on analysis of the mechanism of action of emerging risk factors for the development of atherothrombotic disease including lipoprotein(a) and thrombin-activatable fibrinolysis inhibitor (TAFI). Her approach includes studies of the effect of apolipoprotein(a), the distinguishing protein component of lipoprotein(a), on vascular endothelial cell phenotype and on the processes of thrombosis and fibrinolysis. A component of her research involves studying the secretion of apolipoprotein(a) from hepatocytes and the extracellular assembly of lipoprotein(a) particles; this has led to collaborations with industrial partners who are interested in disruption of lipoprotein(a) assembly as a target for reduction of plasma levels of this lipoprotein. The TAFI project involves analysis of the regulation of gene expression of this anti-fibrinolytic factor using molecular and cellular approaches

Dr. Koschinsky is currently a Full Professor in the Departments of Biochemistry and Physiology at Queen's University in Kingston, Ontario, and is also the Director of the Queen's Cardiac, Circulatory and Respiratory Research Program. For the 2007-2008 year, she is also the Acting Head of the Department of Physiology.

Funding for Dr. Koschinsky's research program comes from the Heart and Stroke Foundation of Ontario as well as from the Canadian Institutes for Health Research. Dr. Koschinsky currently holds a Career Investigator Salary Award from the Heart and Stroke Foundation of Ontario and has received numerous other awards (including a Premier's Research Excellence Award) and delivered many invited lectureships in recognition of her contributions to lipoprotein(a) and TAFI research. In addition to her research program, Dr. Koschinsky has served in many administrative capacities and is currently a member of the Board of Directors of the Heart and Stroke Foundation of Ontario.

---

Jean Marion, PhD
Director, Scientific Affairs
Rx&D
Jean Marion is currently Director, Scientific Affairs at Canada's Research-Based Pharmaceutical Companies (Rx&D) as well as Executive Director of Rx&D's Health Research Foundation. From 1999 to 2001, Jean was seconded to Canada Revenue Agency (CRA). As a National Technology Sector Specialist within CRA's Scientific Research and Experimental Development Program, he played a key role in developing application policies for the pharmaceutical and biopharmaceutical sector. Jean originally joined Rx&D from Merck Frosst Canada where he managed clinical studies as a Clinical Research Project Manager. Prior to joining the private sector, Jean was part of a team at Industry Canada working to improve the business environment affecting the pharmaceutical industry. His career in government also included a posting to the Canadian Embassy in Brussels as a Science and Technology Counsellor and a role in the implementation of the University-Industry Program at the Natural Sciences and Engineering Research Council (NSERC). Jean received a doctorate degree in biochemistry from McGill University in 1980 and held an Industrial Research Fellowship at Ayerst Laboratories and Bioresearch Laboratories.

---

Benjamin Rusak, PhD
Professor, Departments of Psychiatry and Psychology and Director, Research Section
Dalhousie University
Director, Chronobiology and Sleep Program
Queen Elizabeth II Health Sciences Centre
Dr. Rusak graduated from the University of Toronto and received a PhD from the University of California, Berkeley. He is currently a University Research Professor in the Departments of Psychiatry, Psychology and Pharmacology at Dalhousie University. He has served as the Director of Research in Psychiatry since 2000, and in 2003-04 was an Acting Assistant Dean (Research) in the Faculty of Medicine. Dr. Rusak's primary research interests are in the basic mechanisms regulating circadian (daily) rhythms and sleep in mammals, and in applying knowledge of these mechanisms to issues in human health. His current research includes both individual and collaborative projects in the following areas: molecular, neurophysiological and behavioural approaches to circadian and sleep mechanisms; functional brain imaging studies of the effects of sleep deprivation in depression; studies of animal models of depression; and the effects of disrupted sleep on human performance; and on pain syndromes in children. The research contributions of his laboratory have been recognized by his election as a Fellow of the Academy of Sciences of the Royal Society of Canada (1999), his appointment as a Dalhousie Faculty of Science Killam Professor (1995-2000), and as a University Research Professor (2002-07).

Dr. Rusak was the founding Editor of the Journal of Biological Rhythms (1986-94) and has served on the editorial boards of Neuroscience & Biobehavioral Reviews and Sleep, on the Board of Directors of the Canadian Association for Neuroscience, on the International Selection Committee for the Honma Prize for Circadian Rhythmicity, on the Executive of the Society for Research on Biological Rhythms, and as a member of grant review panels for MRC/CIHR, NSERC, NSHRF and NIH (USA). He is currently the Vice-President, Research for the Canadian Sleep Society, a Canadian delegate to the World Federation of Sleep Research Societies, and served as the CIHR University Delegate to Dalhousie (2001-2004).

Dr. Rusak hopes to promote awareness of the significance of circadian rhythmicity and sleep to human health, and of the contributions of circadian factors and sleep disorders to cardiovascular and respiratory disease.

---

Brian Rutt, PhD
Scientist, Imaging Research Laboratories
Robarts Research Institute
Professor, Diagnostic Radiology and Nuclear Medicine
University of Western Ontario
Dr. Brian Rutt is currently a Scientist at the Robarts Research Institute and a Professor at the University of Western Ontario in London, Ontario, where he has been since 1986. Dr. Rutt received graduate degrees from Stanford University and the University of Toronto. He pursued postdoctoral work at the University of California, San Francisco.

Dr. Rutt's research is focused on quantitative measurement of anatomical and functional characteristics of the vasculature using magnetic resonance imaging (MRI). He leads several ongoing projects involving the development of improved methods for acquiring and displaying MR angiograms i.e. images of blood vessels, and assessing atherosclerotic plaque composition, morphology and vulnerability by MRI. He also works on the development of high-speed MRI techniques that will allow the acquisition of complete image sets in seconds rather than minutes. This research is aimed at solving the very real problem of low patient throughput in clinical MRI departments, and in addition is aimed at the development of dynamic scanning methods. Dr. Rutt is also working in the area of MRI hardware development and specifically the development of advanced "receiver coils", which receive the very weak magnetic signals that emanate from the patient's body, and advanced "gradient coils" which produce the spatial resolution in MR images. These coil developments are aimed at improving image quality by customizing coils to patient anatomy.

---

Raphael Saginur, MD, FRCPC
Chief
Division of Infectious Disease
Ottawa Hospital-Civic Campus
Dr. Raphael Saginur is an infectious disease physician and Chief of the Division of Infectious Disease at the Ottawa Hospital-Civic Campus, as well as an Associate Professor of Medicine at the University of Ottawa and President of the Canadian Foundation for Infectious Diseases.

Dr. Saginur received his Bachelor of Arts degree, with a specialty in psychology, at Darmouth College in New Hampshire in 1969, and obtained his medical degree at McGill University (1973). He attended the University of Nairobi in Kenya as part of the McGill-Canadian International Development Agency Project and went on to complete his postdoctoral training at the Jewish General Hospital in Montreal and the Tufts-New England Medical Centre in Boston, Massachusetts.

Dr. Saginur's is an expert in infectious diseases in humans and their impact on public health. His major research interests in this area include bacterial biofilms, which are important in areas such as infections in surgical implants, and cystic fibrosis. He is a representative for the Committee to Advise on Tropical Medicine and Travel, an advisory group for the Public Health Agency of Canada (PHAC) that was created initially for Health Canada in 1990.

Dr. Saginur is also an authority in research ethics and clinical trials of investigational drugs. He chairs the Ottawa Hospital Research Ethics Board and the Oversight Committee of the Ontario Cancer Research Ethics Board. He was founding President of the Canadian Association of Research Ethics Boards.

Dr. Saginur was lead author on the Tutorial of the Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans and is continuing his activity in web-based education in research ethics.

---

Sylvie Stachenko, MD, MSc, FCFP
Dean, School of Public Health
University of Alberta
Sylvie Stachenko is dean of the School of Public Health at the University of Alberta. She was appointed to the position for a five-year term, effective January 1, 2009.

Most recently, Dr. Stachenko served as the Deputy Chief Public Health Officer at the Public Health Agency of Canada. From 2002-2004 she was the director general in the Centre for Chronic Disease Prevention and Control at the Public Health Agency of Canada. From 1997 to 2002, Dr. Stachenko worked with the World Health Organization (WHO) Regional Office for Europe located in Copenhagen, Denmark as the director of Health Policy and Services.

Dr. Stachenko was an associate professor in the Department of Family Medicine at the Université de Montréal, where she served as research director from 1984 to 1988. In 1988, she joined the federal government with the Department of Health and Welfare and, in 1989, was appointed director or Preventive Health Services.

Dr. Stachenko earned a doctorate in medicine from McGill University in 1975. She finished her residency in family medicine at the Université de Montréal in 1977 and she earned a master's degree in epidemiology and health services administration from the Harvard School of Public Health in 1985.

---

Rui Wang, MD, PhD, FAHA
Dr. Rui Wang has been the Vice President (Research) and a Professor of Biology at Lakehead University since 2004. He serves as the Director of Gasotransmitter Research And Training (GREAT) Program of CIHR/ and Heart and Stroke Foundation of Canada. Dr. Wang is also the current Scientific Director of BioNatCom Tech. Inc. Dr. Wang came to Lakehead from the University of Saskatchewan, Department of Physiology, where he was a Professor and the Leader of the Cardiovascular Research Group and of the Cardiovascular and Respiratory Network. Prior to this, Dr. Wang was an Associate Professor at the University of Saskatchewan (1997 to 2001), a Principal Investigator in Mount Desert Island Biolgical Laboratory (Maine, USA) (1995-2003), and an Assistant Professor at the Université de Montréal (1993 to 1997). Dr. Wang was trained in China as a medical doctor, and later received his PhD degree from the University of Alberta in 1990.

Dr. Wang's research focuses on the regulation of cardiovascular health in general. He is an internationally known leader in the study of the metabolism and physiological functions of a group of small molecules of gas, known as gasotrasmitters, including nitric oxide, carbon monoxide, and hydrogen sulfide. His research has been continuously supported by CIHR, NSERC, and Heart and Stroke Foundation of Canada. During the last 5 years, he has received a total of more than $5,000,000 research funding for his research team. In his career, Dr. Wang has published more than 110 peer-reviewed papers in leading scientific journals. He also edited two books and wrote 13 book chapters. He has been invited to give more than 60 lectures and talks all over the world. To date, Dr. Wang has trained more than 40 graduate students, post-doctoral fellows, and visiting scientists.

In his roles of Vice President of Canadian Physiology Society, Associated Editor of Canadian Journal of Physiology and Pharmacology, and editorial member of American Journal of Physiology, Dr. Wang has made significant contributions to advancing physiology science in Canada. Dr. Wang has served many Canadian research funding agencies, including CIHR, Heart and Stroke Foundation, Ministry of Research and Innovation of Ontario, Alberta Heritage Foundation for Medial Research. His service has also been sought by many international research funding agencies, such as USA, Singapore, New Zealand, UK, China, and Hong Kong. Dr. Wang is a Member of International Advisory Committee for Cardiovascular Research Program at Singapore National University, and a Honored Professor of Beijing University and Harbin Medical University of China.

Dr. Wang's achievement has been recognized with numerous honors and awards, including citations in Canadian's Who's Who, the prestigious Fellow of American Physiology Society (2005), Fellow of American Heart Association (2002), Investigator award of CIHR (2000), Stevenson Visiting Professorship of Canadian Physiology Society (1996), Young Investigator Award of Canadian Cardiovascular Society (1995), and McDonald Scholar Award of Canadian Heart and Stroke Foundation (1994).